Results 201 to 210 of about 118,635,816 (237)
Hematology, 2006 Acquired hemophilia A is a rare but severe autoimmune bleeding disorder, resulting from the presence of autoantibodies directed against clotting factor VIII. The etiology of the disorder remains obscure, although approximately half of all cases are associated with other underlying conditions.
Massimo Franchini
exaly +3 more sources
Treatment of acquired hemophilia A [PDF]
Journal of Thrombosis and Haemostasis, 2007 Acquired hemophilia A (AH) is an autoimmune disease that leads to potentially severe bleeding. Management relies on rapid and accurate diagnosis, control of bleeding episodes and eradication of the inhibitor by immunosuppression. There is extensive literature about the disease but only few controlled data are available.
Peter Collins, P W Collins
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Seminars in Thrombosis and Hemostasis, 2012
Acquired hemophilia A is a rare, autoimmune disorder that is caused by autoantibodies that act as inhibitors to factor VIII. It is characterized by severe, unexpected bleeding that may be life-threatening. The incidence of acquired hemophilia A is ~ 0.2 to 1.48 cases per 1 million individuals per year.
Kathryn E Webert
exaly +3 more sources
Acquired hemophilia A is a rare, autoimmune disorder that is caused by autoantibodies that act as inhibitors to factor VIII. It is characterized by severe, unexpected bleeding that may be life-threatening. The incidence of acquired hemophilia A is ~ 0.2 to 1.48 cases per 1 million individuals per year.
Kathryn E Webert
exaly +3 more sources
Advances in Acquired Hemophilia A
Transfusion Medicine Reviews, 2022Acquired Hemophilia A (AHA) is a rare, life-threatening bleeding disorder from autoantibodies against clotting factor VIII. These autoantibodies occur with increasing incidence with advanced age and are often associated with other medical conditions such as autoimmune diseases and malignancy. Not uncommonly, AHA presents as a new bleeding disorder in a
Jacqueline N Poston +1 more
openaire +2 more sources
Acquired hemophilia A: A concise review [PDF]
American Journal of Hematology, 2005 AbstractAcquired hemophilia A is a rare but severe autoimmune bleeding disorder. It is more frequent in the elderly and results from the presence of autoantibodies directed against clotting factor VIII. In this review, we briefly report on the present state of knowledge regarding acquired hemophilia A, analyzing its epidemiology, pathogenesis ...
Giorgio Gandini +2 more
exaly +3 more sources
Acquired hemophilia in malignancy
Thrombosis Research, 2012Acquired hemophilia is a rare but potentially morbid complication in patients with cancer. It may be seen in patients with hematologic neoplasms (usually lymphoproliferative disorders) or with solid tumors. Although the presence of an underlying malignancy portends a worse outcome, the literature suggests that the usual principles of treatment ...
Brandi N, Reeves, Nigel S, Key
openaire +2 more sources
Immunotherapy of acquired hemophilia A
Hematology, 2023Abstract Acquired hemophilia A (AHA) is an autoimmune disorder characterized by the formation of autoantibodies that neutralize the function of coagulation factor VIII. Immunosuppressive therapy (IST) with glucocorticoids, cyclophosphamide, rituximab, or combinations thereof is the standard of care to suppress autoantibody formation and ...
openaire +2 more sources
Journal of Thrombosis and Haemostasis, 2012 Background: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding.
Pascual Marco +2 more
exaly +2 more sources
Acta Medica Scandinavica, 1980
ABSTRACT. Acquired hemophilia A due to antibodies of factor VIII procoagulant activity is rare. This paper reports 11 such patients followed up for long periods. They exemplify various forms of associated disorders. Four of them have died from hemorrhages, 4 have had complete remission and 3 are still alive with persistent inhibitors.
I M, Nilsson, S, Lamme
openaire +2 more sources
ABSTRACT. Acquired hemophilia A due to antibodies of factor VIII procoagulant activity is rare. This paper reports 11 such patients followed up for long periods. They exemplify various forms of associated disorders. Four of them have died from hemorrhages, 4 have had complete remission and 3 are still alive with persistent inhibitors.
I M, Nilsson, S, Lamme
openaire +2 more sources
Emicizumab for the treatment of acquired hemophilia A
Blood, 2021Abstract Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents and human or porcine FVIII are currently standard of care.
Paul Knoebl +5 more
openaire +2 more sources